Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection

SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection

(2022) Paul Feuerstadt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial

(2022) Robert Orenstein et al.   BMC INFECTIOUS DISEASES

Mortality, Health Care Use, and Costs of Clostridioides difficile Infections in Older Adults

(2022) Paul Feuerstadt et al.   Journal of the American Medical Directors Association

Long-term Safety of Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection

(2021) Srishti Saha et al.   GASTROENTEROLOGY

ACG Clinical Guidelines

(2021) Colleen R. Kelly et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults

(2021) Stuart Johnson et al.   CLINICAL INFECTIOUS DISEASES

Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection

(2021) Paul Feuerstadt et al.   DIGESTIVE DISEASES AND SCIENCES

Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes

(2020) Alice Y. Guh et al.   NEW ENGLAND JOURNAL OF MEDICINE

Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant

(2019) Zachariah DeFilipp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660—A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection

(2018) Erik R Dubberke et al.   CLINICAL INFECTIOUS DISEASES

Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)

(2018) L Clifford McDonald et al.   CLINICAL INFECTIOUS DISEASES

Low Cure Rates in Controlled Trials of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection: A Systematic Review and Meta-Analysis

(2018) Raseen Tariq et al.   CLINICAL INFECTIOUS DISEASES

Adverse events in faecal microbiota transplant: a review of the literature

(2016) M. Baxter et al.   JOURNAL OF HOSPITAL INFECTION

Safety and Durability of RBX2660 (Microbiota Suspension) for RecurrentClostridium difficileInfection: Results of the PUNCH CD Study

(2015) Robert Orenstein et al.   CLINICAL INFECTIOUS DISEASES

Treating Clostridium difficile Infection With Fecal Microbiota Transplantation

(2011) Johan S. Bakken et al.   Clinical Gastroenterology and Hepatology